Pneumococcal vaccine is expected to cost $40-$46 per dose for the public sector, a 20%-25% discount to its private sector price of $58, Wyeth tells Advisory Committee on Immunization Practices June 21. ACIP voted to include Prevnar in the Vaccines for Children program for children up to 59 months of age. Separately, ACIP revised its Prevnar use recommendation to include immunization of all children less than 23 months of age and those aged 24 to 59 months at high risk for invasive disease. Immunization with a single dose of Prevnar or PPV23 "may be considered" for children 24 to 59 months of age who are of American Indian, Alaska Native or African American descent and attend out-of-home day care. Previously, ACIP had included the children of these ethnic groups in the "recommended" category
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth